RxDoctor Payments Data

Britni Hebert, MD

Internal Medicine · Lafayette, LANPI 1215198452

Payments from drug & device makers

$3,086in general payments, 2019–2025

Across 196 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$344
  • AbbVie$282
  • Pfizer$277
  • Lilly USA, LLC$272
  • Novo Nordisk$238
  • AstraZeneca$234
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$3,072100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,086 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$288,968
Medicare patients
539
Services billed
3,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide161$188,392
EliquisApixaban107$82,773
TrulicityDulaglutide68$68,378
OzempicSemaglutide45$41,167
MyrbetriqMirabegron48$34,203
LinzessLinaclotide27$18,646
XareltoRivaroxaban22$13,411
ArexvyRsvpref3 Antigen/As01e/Pf38$11,918
ShingrixVaricella-Zoster Ge/As01b/Pf44$9,780
Tresiba Flextouch U-100Insulin Degludec14$6,887
Atorvastatin Calcium307$5,586
Rosuvastatin Calcium420$5,549
Pantoprazole Sodium210$4,968
Levothyroxine Sodium462$4,853
Breo ElliptaFluticasone/Vilanterol12$4,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$272$256,770229 claims
PfizerEliquis$277$82,773107 claims
Novo NordiskOzempic$238$41,16745 claims
Astellas Pharma US IncMyrbetriq$80$34,20348 claims
GSKArexvy, Shingrix, Breo Ellipta$177$26,50994 claims
AbbVieLinzess, Synthroid$282$22,96992 claims
Johnson & JohnsonXarelto$52$13,41122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →